Lymphocyte subset analyses in healthy adults vaccinated with yellow fever 17DD virus
- PMID: 16113878
- DOI: 10.1590/s0074-02762005000300021
Lymphocyte subset analyses in healthy adults vaccinated with yellow fever 17DD virus
Erratum in
- Mem Inst Oswaldo Cruz. 2005 Aug;100(5):2 p following 571
Abstract
In this study the kinetics of humoral and cellular immune responses in first-time vaccinees and re-vaccinees with the yellow fever 17DD vaccine virus was analyzed. Flow cytometric analyses were used to determine percentual values of T and B cells in parallel to the yellow fever neutralizing antibody production. All lymphocyte subsets analyzed were augmented around the 30th post vaccination day, both for first-time vaccinees and re-vaccinees. CD3+ T cells increased from 30.8% (SE +/- 4%) to 61.15% (SE +/- 4.2%), CD4+ T cells from 22.4% (SE +/- 3.6%) to 39.17% (SE +/- 2%) with 43% of these cells corresponding to CD4+CD45RO+ T cells, CD8+ T cells from 15.2% (SE +/- 2.9%) to 27% (SE +/- 3%) with 70% corresponding to CD8+CD45RO+ T cells in first-time vaccinees. In re-vaccinees, the CD3+ T cells increased from 50.7% (SE +/- 3%) to 80% (SE +/- 2.3%), CD4+ T cells from 24.9% (SE +/- 1.4%) to 40% (SE +/- 3%) presenting a percentage of 95% CD4+CD45RO+ T cells, CD8+ T cells from 19.7% (SE +/- 1.8%) to 25% (SE +/- 2%). Among CD8+CD38+ T cells there could be observed an increase from 15 to 41.6% in first-time vaccinees and 20.7 to 62.6% in re-vaccinees. Regarding neutralizing antibodies, the re-vaccinees presented high titers even before re-vaccination. The levels of neutralizing antibodies of first-time vaccinees were similar to those presented by re-vaccinees at day 30 after vaccination, indicating the success of primary vaccination. Our data provide a basis for further studies on immunological behavior of the YF 17DD vaccine.
Similar articles
-
Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection.J Med Virol. 1998 Oct;56(2):159-67. doi: 10.1002/(sici)1096-9071(199810)56:2<159::aid-jmv10>3.0.co;2-b. J Med Virol. 1998. PMID: 9746073
-
Booster dose after 10 years is recommended following 17DD-YF primary vaccination.Hum Vaccin Immunother. 2016;12(2):491-502. doi: 10.1080/21645515.2015.1082693. Hum Vaccin Immunother. 2016. PMID: 26360663 Free PMC article.
-
17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children.PLoS One. 2012;7(12):e49828. doi: 10.1371/journal.pone.0049828. Epub 2012 Dec 10. PLoS One. 2012. PMID: 23251351 Free PMC article. Clinical Trial.
-
Understanding the role of innate immunity in the mechanism of action of the live attenuated Yellow Fever Vaccine 17D.Adv Exp Med Biol. 2007;590:43-53. doi: 10.1007/978-0-387-34814-8_3. Adv Exp Med Biol. 2007. PMID: 17191376 Review. No abstract available.
-
Yellow fever vaccine: past, present and future.Expert Opin Biol Ther. 2008 Nov;8(11):1787-95. doi: 10.1517/14712598.8.11.1787. Expert Opin Biol Ther. 2008. PMID: 18847312 Review.
Cited by
-
Historical review of clinical vaccine studies at Oswaldo Cruz Institute and Oswaldo Cruz Foundation--technological development issues.Mem Inst Oswaldo Cruz. 2015 Feb;110(1):114-24. doi: 10.1590/0074-02760140346. Epub 2015 Jan 16. Mem Inst Oswaldo Cruz. 2015. PMID: 25742271 Free PMC article. Review.
-
Dynamics of the cytotoxic T cell response to a model of acute viral infection.J Virol. 2015 Apr;89(8):4517-26. doi: 10.1128/JVI.03474-14. Epub 2015 Feb 4. J Virol. 2015. PMID: 25653453 Free PMC article.
-
Effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on immune responses to vaccines among rural Ugandan adolescents: randomised controlled trial protocol B for the 'POPulation differences in VACcine responses' (POPVAC) programme.BMJ Open. 2021 Feb 16;11(2):e040427. doi: 10.1136/bmjopen-2020-040427. BMJ Open. 2021. PMID: 33593769 Free PMC article.
-
Cellular inflammatory response to flaviviruses in the central nervous system of a primate host.J Histochem Cytochem. 2009 Oct;57(10):973-89. doi: 10.1369/jhc.2009.954180. Epub 2009 Jul 6. J Histochem Cytochem. 2009. PMID: 19581627 Free PMC article.
-
Yellow fever virus vaccination: an emblematic model to elucidate robust human immune responses.Hum Vaccin Immunother. 2021 Aug 3;17(8):2471-2481. doi: 10.1080/21645515.2021.1891752. Epub 2021 Apr 28. Hum Vaccin Immunother. 2021. PMID: 33909542 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials